SSA
RARE icon

Schonfeld Strategic Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Schonfeld Strategic Advisors’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-23,000
Closed -$529K – 2588
2025
Q4 		$529K Buy
+23,000
New +$756K ﹤0.01% 1375
2025
Q1 		– Sell
-50,000
Closed -$2.1M – 2450
2024
Q4 		$2.1M Buy
+50,000
New +$2.48M 0.01% 811

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Schonfeld Strategic Advisors's RARE Position: Q2 2026 in Review

Schonfeld Strategic Advisors reduced its Ultragenyx Pharmaceutical (RARE) stake by 89% in Q2 2026, selling an estimated $11M and leaving 52,881 shares worth $1.77M. The position accounts for 0.01% of the portfolio, ranked #1135.

Schonfeld Strategic Advisors first reported a position in RARE in Q1 2017 and has held it in 22 quarters since. The position peaked at $34.4M in Q3 2025. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Schonfeld Strategic Advisors held 52,881 shares of Ultragenyx Pharmaceutical worth $1.77M as of Q2 2026.
  • Schonfeld Strategic Advisors sold 441,856 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $11M.
  • Ultragenyx Pharmaceutical made up 0.01% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #1135 holding.
  • Schonfeld Strategic Advisors first reported a position in Ultragenyx Pharmaceutical in Q1 2017 and has held it in 22 quarters since.
  • Schonfeld Strategic Advisors's Ultragenyx Pharmaceutical position peaked at $34.4M in Q3 2025.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.